Altimmune stock: 48-week pemvidutide MASH data, FDA Breakthrough Therapy boost, but rising competition and cash needs. Click ...

Patients with idiopathic pulmonary fibrosis-associated chronic cough who received twice-daily oral extended release ...

Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...

Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule glucagon-like ...

Despite receiving devices, education, and support, only one-third regularly took morning and night BP measurements as ...

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...

Low-sodium oxybate reduces 24-hour sleep duration and daytime napping in adults with idiopathic hypersomnia, according to a phase 3 trial analysis.

Clinicians who use the tool more often are less likely to order diagnostic tests and GDMT, even for HFrEF patients.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

Topline data expected in 1Q 2028Phase 2bipolar depression trial initiation follows positive Phase 2 results in acute schizophreniaNEW YORK, Jan.

"Lower dose does not mean lower responsibility." ...

Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ...